Double-blind treatment of apathy in patients with poststroke depression using nefiracetam

Journal of Neuropsychiatry and Clinical Neurosciences

Volumn 21, Issue 2, 2009, Pages 144-151

  Robinson, Robert G ^a   Jorge, Ricardo E ^a   Clarence Smith, Kathleen ^b   Starkstein, Sergio ^c  

^a UNIVERSITY OF IOWA   (United States)

^b Prestwick Scientific Capital   (United States)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

NEFIRACETAM; PLACEBO;

ADULT; AGED; APATHY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFECT; FEMALE; GASTROINTESTINAL SYMPTOM; HEART DISEASE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MOOD DISORDER; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SCORING SYSTEM; SKIN DISEASE; STROKE; TREATMENT DURATION; VASCULAR DISEASE;

EID: 67749124212     PISSN: 08950172     EISSN: None     Source Type: Journal    
DOI: 10.1176/jnp.2009.21.2.144     Document Type: Article

References (46)

1. Marin RS: Apathy: a neuropsychiatric syndrome. J Neuropsychiatry Clin Neurosci 1991; 3:243-254
2. Starkstein SE, Fedoroff JP, Price TR, et al: Apathy following cerebrovascular lesions. Stroke 1993; 24:1625-1630
3. Levy R, Dubois B: Apathy and the functional anatomy of the prefrontal cortex-basal ganglia circuits. Cereb Cortex 2006; 16:916-928 (Pubitemid 43992442)
4. Marin RA, Chakravorty S: Disorders of diminished motivation, in Textbook of Traumatic Brain Injury. Edited by Silver JM, McAllister TW, Yudofsky SC. Arlington, Va, American Psychiatric Publishing, 2005, pp 337-352
5. Starkstein SE, Petracca G, Chemerinski E, et al: Syndromic validity of apathy in Alzheimer's disease. Am J Psychiatry 2001; 158:872-877 (Pubitemid 32547615)
6. Marin RS: Reliability and validity of the apathy evaluation scale. Psychiatry Res 1991; 38:143-162
7. Starkstein SE, Mayberg HS, Preziosi TJ, et al: Reliability, validity and clinical correlates of apathy in Parkinson's disease. J Neuropsychiatr Clin Neurosci 1992; 4:134-139
8. Marin RS, Firinciogullari S, Biedrzicky RC: The sources of convergence between measures of apathy and depression. J Affect Disord 1993; 28:117-124 (Pubitemid 23178099)
9. Watanabe A, Matsuo K, Kato N, et al: Cerebrovascular response to cognitive tasks and hyperventilation measured by multi-channel near-infrared spectroscopy. J Neuropsychiatry Clin Neurosci 2003; 15:442-449 (Pubitemid 37444587)
10. Van Reekum R, Bayley M, Garner S, et al: N of 1 study: amantadine for the amotivational syndrome in a patient with traumatic brain injury. Brain Inj 1995; 9:49-53
11. Newburn G, Newburn D: Selegiline in the management of apathy following traumatic brain injury. Brain Inj 2005; 19: 149-154 (Pubitemid 40259752)
12. Kraus MF: Neuropsychiatric sequelae of stroke and traumatic brain injury: the role of psychostimulants. Int J Psychiatry Med 1995; 25:39-51
13. Tsuchiya Y, Takahashi Y, Jindo T, et al: Comprehensive evaluation of canine renal papillary necrosis induced by nefiracetam, a neurotransmission enhancer. Eur J Pharmacol 2003; 475:119-128 (Pubitemid 37088015)
14. Nishizaki T, Matsuoka T, Nomura T, et al: Nefiracetam modulates acetylcholine receptor currents via two different signal transduction pathways. Mol Pharmacol 1998; 53:1-5 (Pubitemid 28068366)
15. Kitano Y, Komiyama C, Makino M, et al: Effects of nefiracetam, a novel pyrrolidone-type nootropic agent, on the amygdala- kindled seizures in rats. Epilepsia 2005; 46:1561-1568 (Pubitemid 44921929)
16. Moriguchi S, Marszalec W, Zhao X, et al: Potentiation of N-methyl- D-aspartate-induced currents by the nootropic drug nefiracetam in rat cortical neurons. J Pharmacol Exp Ther 2003; 307:160-167 (Pubitemid 37151902)
17. Narahashi T, Moriguchi S, Zhao X, et al: Mechanisms of action of cognitive enhancers on neuroreceptors. Biol Pharm Bull 2004; 27:1701-1706 (Pubitemid 41701591)
18. Zhao X, Yeh JZ, Narahashi T: Post-stroke dementia: nootropic drug modulation of neuronal nicotinic acetylcholine receptors. Ann NY Acad Sci 2001; 939:179-186 (Pubitemid 32620066)
19. Moriguchi S, Shioda N, Maejima H, et al: Nefiracetam potentiates N-methyl-D-aspartate (NMDA) receptor function via protein kinase C activation and reduces magnesium block of NMDA receptor. Mol Pharmacol 2007; 71:580-587 (Pubitemid 46147922)
20. Ando T, Takagi N, Takagi K, et al: Effects of nefiracetam on the levels of brain-derived neurotrophic factor and synapsin I MRNA and protein in the hippocampus of microsphere-embolized rats. Eur J Pharmacol 2005; 507(1-3):49-56 (Pubitemid 40126840)
21. Jin J, Watabe S, Yamamoto T: Nefiracetam improves the impairment of local cerebral blood flow and glucose utilization after chronic focal cerebral ischemia in rats. Pharmacology 2002; 64:119-125 (Pubitemid 34136852)
22. Otomo E, Kogure K, Hirai S, et al: [Clinical utility of DM-9384 (Nefiracetam) in patients with aftereffect following cerebrovascular disorders: a comparative double-blind study with idebenone]. Rinsho Iyaku (J Clin Ther Med) 1994; 10:1871-1918 (Japanese)
23. Robinson RG, Jorge RE, Moser DJ, et al: Escitalopram and problem solving therapy for prevention of poststroke depression: a randomized trial. JAMA 2008; 299:2391-2400
24. Wing JK, Cooper JE, Sartorius N. The Measurement and Classification of Psychiatric Symptoms: An Instructional Manual for the PSE and CATEGO Programs. New York, Cambridge University Press, 1974
25. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorder-DSM-IV-TR. Washington, DC, American Psychiatric Association, 2000
26. Hamilton MA: A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23:56-62
27. Beck AT, Steer RA: Beck Depression Inventory manual. San Antonio, The Psychological Corporation, 1987
28. Robinson RG, Starr LB, Kubos KL, et al: A two-year longitudinal study of post-stroke mood disorders: findings during the initial evaluation. Stroke 1983; 14:736-744
29. House A, Dennis M, Warlow C, et al: Mood disorders after stroke and their relation to lesion location. A CT scan study Brain 1990; 113:1113-1130 (Pubitemid 20267476)
30. Teng EL, Chui HC: The modified mini-mental state (3MS) examination. J Clin Psychiatry 1987; 48:314-318
31. Forer S, Granger CV: Functional Independence Measure. Buffalo, NY, The Buffalo General Hospital State University of New York at Buffalo, 1987
32. Kunitz SC, Gross CR, Heyman A, et al: The pilot stroke data bank: definition, design, and data. Stroke 1984; 15:740-746 (Pubitemid 14090257)
33. Levy R, Dubois B: Apathy and the functional anatomy of the prefrontal cortex-basal ganglia circuits. Cereb Cortex 2006; 16:916-928 (Pubitemid 43992442)
34. Plenger PM, Dixon CE, Castillo RM, et al: Subacute methylphenidate treatment for moderate to moderately severe traumatic brain injury: a preliminary double-blind placebo-controlled study. Arch Phys Med Rehabil 1996; 77:536-540
35. Zafonte RD, Lexell J, Cullen N: Possible applications for dopaminergic agents following traumatic brain injury, part 2. J Head Trauma Rehabil 2001; 16:112-116 (Pubitemid 33608947)
36. Whyte J, Vaccaro M, Grieb-Neff P, et al: Psychostimulant use in the rehabilitation of individuals with traumatic brain injury. J Head Trauma Rehabil 2002; 17:284-299 (Pubitemid 34809594)
37. Kraus MF, Maki P: The combined use of amantadine and L-dopa/carbidopa in the treatment of chronic brain injury. Brain Inj 1997; 11:455-460 (Pubitemid 27229210)
38. Kraus MF, Maki PM: Effect of amantadine hydrochloride on symptoms of frontal lobe dysfunction in brain injury: case studies and review. J Neuropsychiatry Clin Neurosci 1997; 9:222-230
39. Meythaler JM, Brunner RC, Johnson A, et al: Amantadine to improve neurorecovery in traumatic brain injury-associated diffuse axonal injury: a pilot double-blind randomized trial. J Head Trauma Rehabil 2002; 17:300-313 (Pubitemid 34809595)
40. Arciniegas D, Adler L, Topkoff J, et al: Attention and memory dysfunction after traumatic brain injury: cholinergic mechanisms, sensory gating, and a hypothesis for further investigation. Brain Inj 1999; 13:1-13 (Pubitemid 29043314)
41. Freo U, Pizzolato G, Dam M, et al: A short review of cognitive and functional neuroimaging studies of cholinergic drugs: implications for therapeutic potentials. J Neural Transm 2002; 109:857-870 (Pubitemid 34810778)
42. Arciniegas DB: The cholinergic hypothesis of cognitive impairment caused by traumatic brain injury. Curr Psychiatry Rep. Oct 2003; 5:391-399
43. Cummings JL, Koumaras B, Chen M, et al: Effects of rivastigmine treatment on the neuropsychiatric and behavioral disturbances of nursing home residents with moderate to severe probable Alzheimer's disease: a 26-week, multicenter, openlabel study. Am J Geriatr Pharmacother 2005; 3:137-148 (Pubitemid 41644452)
44. Kalivas PW, Volkow N, Seamans J: Unmanageable motivation in addiction: a pathology in prefrontal-accumbens glutamate transmission. Neuron 2005; 45:647-650 (Pubitemid 40320699)
45. Okada K, Kobayashi S, Yamagata S, et al: Poststroke apathy and regional cerebral blood flow. Stroke 1997; 28:2437-2441 (Pubitemid 28007646)
46. Yamagata S, Yamaguchi S, Kobayashi S: Impaired novelty processing in apathy after subcortical stroke. Stroke 2004; 35: 1935-1940 (Pubitemid 38971879)